CD40 and systemic lupus erythematosus: Multiple anti-CD40L or anti-CD40 drugs have been developed to reduce the risk of thromboembolic complications, such as dapirolizumab pegol (CDP7657) and VIB4920 in lupus, diabetes, Sjogren disease, and other autoimmune diseases.